Board of Directors
President and Chief Executive Officer, Sangart, Inc.
San Diego, CA
Leucadia National Corporation
Salt Lake City, UT
President and Chief Executive Officer
Mr. O'Callaghan joined Sangart as President and Chief Executive Officer in June 2008. Mr. O'Callaghan brings a breadth of experience to Sangart, having held senior positions with a number of pharmaceutical and biotechnology companies in both Europe and the US. These include senior positions with Pfizer in the UK and Merck Serono in Germany, before becoming President and CEO of BioPartners, a Swiss based biotechnology company. Since relocating to the US, Mr. O'Callaghan has held senior management positions at Novartis, where he served as General Manager of their Transplantation, Immunology and Infectious Disease businesses, as well as at Covance, a clinical research firm, where he served as General Manager of their Cardiac safety and IVRS businesses. Mr. O'Callaghan joins Sangart from NPS Pharmaceuticals, where he served as Chief Commercial Officer. Mr. O'Callaghan brings his extensive general management background in the pharmaceutical, biotechnology and clinical research sectors, as well as his significant international experience, to lead Sangart through regulatory submission and commercial launch of MP4.Leucadia National Corporation
Mr. Wheeler is currently employed as President of the Asset Management Group of Leucadia National Corporation, a New York-based holding company. Mr. Wheeler has extensive management experience and also currently serves as the Chairman of Conwed Plastics and on the Board of Directors of International Assets Holding Corporation. Prior positions held include President and Chief Executive Officer of American Investment Bank, N.A. Mr. Wheeler holds a Bachelor of Science and Arts from Utah State University and an M.B.A. from Brigham Young University.